Advertisement
Canada Markets open in 52 mins

  • S&P/TSX

    22,375.83
    +116.63 (+0.52%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • CAD/USD

    0.7326
    +0.0015 (+0.2088%)
     

  • CRUDE OIL

    79.70
    +0.44 (+0.56%)
     

  • BTC-CAD

    86,414.66
    +2,612.48 (+3.12%)
     

  • CMC Crypto 200

    1,307.57
    -50.44 (-3.73%)
     

  • GOLD FUTURES

    2,372.50
    +32.20 (+1.38%)
     

  • RUSSELL 2000

    2,073.63
    +18.49 (+0.90%)
     

  • 10-Yr Bond

    4.4750
    +0.0260 (+0.58%)
     

  • NASDAQ futures

    18,297.00
    +82.50 (+0.45%)
     

  • VOLATILITY

    12.77
    +0.08 (+0.63%)
     

  • FTSE

    8,445.09
    +63.74 (+0.76%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6795
    +0.0017 (+0.25%)
     

Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

Solid Biosciences Inc.
·1 min read

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 8:20 am ET. Following the prepared remarks, several members of the leadership team will be available for Q&A.

Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for approximately 30 days on the Events page.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com